secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001477932-22-008523
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx reports Q3 2022 results; cash $16.4M, monthly burn ~$2.3M; new global vet supply deal
--------------------------------------------------------------------------------

- Cash at Sep 30: $16.4M; net cash used in operations ~$2.3M/month.
- Raised ~$6.4M net from public offering; secured $1.5M non-dilutive from Namur Invest.
- Post-quarter: signed global supply agreement for Nu.Q Vet Cancer Test with a pet healthcare market leader; launched via Heska in U.S. and soon Europe.
- Appointed DXOCRO for U.S. clinical validation studies of Nu.Q NETs and Cancer tests; pre-submission to FDA anticipated in 2023.
- Started lung cancer biomarker study with Hospices Civils de Lyon (ILYAD) to develop national screening program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/0001477932-22-008523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-22-008523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer